Vivani Medical Announces Participation in Upcoming Investor Conferences
vivani | September 3, 2026
Read More
Vivani Medical Reports Second Quarter 2026 Financial Results and Provides Business Update
vivani | August 13, 2026
Read More
Vivani Medical Announces Successful Dosing of All Participants in SLIM-1, a Phase 1 Trial Evaluating NPM-139, a Miniature, Ultra Long-Acting Semaglutide Implant for Chronic Weight Management
vivani | August 6, 2026
Read More
Vivani Medical to Present at the Emerging Growth Conference on July 15, 2026
vivani | July 14, 2026
Read More
Vivani Medical Enters into Agreement with Novo Nordisk to Evaluate NPM-139, a Miniature, Ultra Long-Acting Semaglutide Implant for Chronic Weight Management
vivani | July 7, 2026
Read More
Vivani Announces Entry into Merger Agreement Between Wholly Owned Subsidiary Cortigent, Inc. and Nasdaq-listed ClearOne, Inc.
vivani | July 2, 2026
Read More
Vivani Medical Announces Appointment of August J. Moretti to Board of Directors and Retirement of Dr. Dean Baker
vivani | June 26, 2026
Read More
Vivani Medical Receives Regulatory Approval for the Initiation of SLIM-1, a Phase 1 Clinical Trial of NPM-139 Semaglutide Implant in Obesity and Chronic Weight Management
vivani | June 25, 2026
Read More
Vivani Medical Reports First Quarter 2026 Financial Results and Provides Business Update
vivani | May 13, 2026
Read More
Vivani Medical Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
vivani | March 26, 2026
Read More
Blog Navigation
Contact Us
To learn more about Vivani, and to learn more about NPM-139 (semaglutide implant) or the other programs in our pipeline, please fill out this form.